Boston Scientific Corp (BSX)

Pretax margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm) US$ in thousands 1,984,000 1,929,000 1,565,000 1,484,000 1,194,000 866,000 1,104,000 908,000 1,078,000 991,000 281,000 -48,000 -350,000 -4,609,000 -4,291,000 -3,966,000 -3,532,000 513,000 878,000 1,079,000
Revenue (ttm) US$ in thousands 13,974,000 10,508,000 10,348,000 9,999,000 9,228,000 12,104,000 11,689,000 11,502,000 11,625,000 11,168,000 10,855,000 9,774,000 9,553,000 9,751,000 9,790,000 10,420,000 10,349,000 10,035,000 9,758,000 9,649,000
Pretax margin 14.20% 18.36% 15.12% 14.84% 12.94% 7.15% 9.44% 7.89% 9.27% 8.87% 2.59% -0.49% -3.66% -47.27% -43.83% -38.06% -34.13% 5.11% 9.00% 11.18%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $1,984,000K ÷ $13,974,000K
= 14.20%

Boston Scientific Corp.'s pretax margin has shown a positive trend over the past eight quarters, indicating improving profitability before taxes. In Q4 2023, the company achieved the highest pretax margin of 13.95%, reflecting efficient cost management and revenue generation. This represents a significant increase from Q1 2022, where the pretax margin was at 7.45%.

The consistent upward trajectory in pretax margin suggests that Boston Scientific Corp. has been successful in controlling operating expenses and maximizing profits before accounting for taxes. This improvement could be attributed to factors such as revenue growth, cost-cutting measures, operational efficiencies, or a combination of these elements.

Overall, the trend in the pretax margin indicates that Boston Scientific Corp. has been effectively managing its financial performance and is on a positive trajectory in terms of profitability.


Peer comparison

Dec 31, 2023